UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma

Journal of clinical oncology, 2018-12, Vol.36 (35), p.JCO1800632-3458

2018

Volltextzugriff (PDF)

Strategies to reverse melanoma-induced T-cell dysfunction

Clinics in dermatology, 2013-05, Vol.31 (3), p.251-256

2013

Volltextzugriff (PDF)

TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients

The Journal of clinical investigation, 2015-05, Vol.125 (5), p.2046-2058

2015

Volltextzugriff (PDF)

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients

The Journal of experimental medicine, 2010-09, Vol.207 (10), p.2175-2186

2010

Volltextzugriff (PDF)

IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells

Cancer research (Chicago, Ill.), 2015-04, Vol.75 (8), p.1635-1644

2015

Volltextzugriff (PDF)

CD8+ T Cells Specific for Tumor Antigens Can Be Rendered Dysfunctional by the Tumor Microenvironment through Upregulation of the Inhibitory Receptors BTLA and PD-1

Cancer research (Chicago, Ill.), 2012-02, Vol.72 (4), p.887-896

2012

Volltextzugriff (PDF)

PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen-Specific CD8+ T Cells Induced by Melanoma Vaccines

Cancer research (Chicago, Ill.), 2014-02, Vol.74 (4), p.1045-1055

2014

Volltextzugriff (PDF)

CD226 opposes TIGIT to disrupt Tregs in melanoma

JCI insight, 2018-07, Vol.3 (14)

2018

Volltextzugriff (PDF)

PD-1 Is a Regulator of NY-ESO-1-Specific CD8+ T Cell Expansion in Melanoma Patients

The Journal of immunology (1950), 2009-05, Vol.182 (9), p.5240-5249

2009

Volltextzugriff (PDF)

Such a long wait: Three-dimensional paediatric transoesophageal echocardiography finally arises

Archives of cardiovascular diseases, 2023-01, Vol.116 (1), p.1-2

2023

Volltextzugriff (PDF)

Abstract 4046: Interleukin-10 and programmed death-1 cooperate to regulate tumor antigen-specific CD8+ T cells in melanoma patients

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.4046-4046

2015

Volltextzugriff (PDF)

Abstract 1574: Quantitation of HLA-A2-MAGE3271-279 complexes on the DC surface improves anticancer vaccine designs

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.1574-1574

2012

Volltextzugriff (PDF)

IL-10 and PD-1 cooperate to limit the activity of tumor-specific CD8+ T cells

Cancer research (Chicago, Ill.), 2015-02, Vol.75 (8), p.1635-1644

2015

Volltextzugriff (PDF)

Human tumor antigen-specific helper and regulatory T cells share common epitope specificity but exhibit distinct T cell repertoire

The Journal of immunology (1950), 2010-06, Vol.184 (12), p.6709-6718

2010

Volltextzugriff (PDF)

Abstract 459: Targeting TIGIT and PD-1 to increase the expansion and function of tumor antigen-specific CD8+ T cells in melanoma patients

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.459-459

2015

Volltextzugriff (PDF)

Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients

Journal of immunotherapy, 2008-10, Vol.31 (8), p.781-791

2008

Volltextzugriff (PDF)

Study of anti-PD-1 antibody pembrolizumab and pegylated-interferon alfa-2b (Peg-IFN) for advanced melanoma

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e20018-e20018

2015

Volltextzugriff (PDF)

Tim-3 is expressed by a majority of NK cells at periphery but not at tumor site in patients with advanced melanoma (TUM2P.919)

The Journal of immunology (1950), 2014-05, Vol.192 (1_Supplement), p.71-71.43

2014

Volltextzugriff (PDF)

TIGIT and PD-1 impair tumor antigen-specific CD8^sup +^ T cells in melanoma patients

The Journal of clinical investigation, 2015-05, Vol.125 (5), p.2046

2015

Volltextzugriff (PDF)

TIGIT and PD-1 impair tumor antigen-specific CD8 super( +) T cells in melanoma patients

The Journal of clinical investigation, 2015-05, Vol.125 (5), p.2046-2046

2015

Volltextzugriff (PDF)

TIGIT and PD-1 impair tumor antigen-specific [CD8.sup.+] T cells in melanoma patients

The Journal of clinical investigation, 2015-05, Vol.125 (5), p.2046

2015

Volltextzugriff (PDF)

Tolerance analysis using a Computer Aided Tolerancing Software: ANATOLE 3D

Procedia CIRP, 2018, Vol.75, p.267-272

2018

Volltextzugriff (PDF)

Phase IB study of pembrolizumab (Pembro) and pegylated-interferon alfa-2b (Peg-IFN) in advanced melanoma (MEL)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.9539-9539

2016

Volltextzugriff (PDF)

The upregulation of the inhibitory receptors BTLA and PD-1 defines a novel subset of dysfunctional tumor antigen-specific CD8+ T cells (127.19)

The Journal of immunology (1950), 2012-05, Vol.188 (1_Supplement), p.127-127.19

2012

Volltextzugriff (PDF)

Abstract 4576: Immunization with CPG in combination with MHC class I and class II peptides stimulates rapid and strong tumor antigen-specific CTL responses in melanoma patients

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.4576-4576

2013

Volltextzugriff (PDF)

1 – 25 von 84

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(78)
Mit Volltextzugriff
(75)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(40)
Life Sciences & Biomedicine
(37)
Humans
(32)
Life Sciences
(13)
Oncology
(13)
Male
(12)
Melanoma - Immunology
(12)
Female
(11)
Immunology
(11)
Middle Aged
(10)
Antigens, Neoplasm - Immunology
(8)
Patients
(6)
Prostate Cancer
(6)
Aged
(5)
Biological And Medical Sciences
(5)
Cd8-Positive T-Lymphocytes - Immunology
(5)
Epitopes, T-Lymphocyte - Immunology
(5)
Human Health And Pathology
(5)
Medical Sciences
(5)
Medicine, Research & Experimental
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma

Strategies to reverse melanoma-induced T-cell dysfunction

TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients

IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells

CD8+ T Cells Specific for Tumor Antigens Can Be Rendered Dysfunctional by the Tumor Microenvironment through Upregulation of the Inhibitory Receptors BTLA and PD-1

PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen-Specific CD8+ T Cells Induced by Melanoma Vaccines

CD226 opposes TIGIT to disrupt Tregs in melanoma

PD-1 Is a Regulator of NY-ESO-1-Specific CD8+ T Cell Expansion in Melanoma Patients

Such a long wait: Three-dimensional paediatric transoesophageal echocardiography finally arises

Abstract 4046: Interleukin-10 and programmed death-1 cooperate to regulate tumor antigen-specific CD8+ T cells in melanoma patients

Abstract 1574: Quantitation of HLA-A2-MAGE3271-279 complexes on the DC surface improves anticancer vaccine designs

IL-10 and PD-1 cooperate to limit the activity of tumor-specific CD8+ T cells

Human tumor antigen-specific helper and regulatory T cells share common epitope specificity but exhibit distinct T cell repertoire

Abstract 459: Targeting TIGIT and PD-1 to increase the expansion and function of tumor antigen-specific CD8+ T cells in melanoma patients

Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients

Study of anti-PD-1 antibody pembrolizumab and pegylated-interferon alfa-2b (Peg-IFN) for advanced melanoma

Tim-3 is expressed by a majority of NK cells at periphery but not at tumor site in patients with advanced melanoma (TUM2P.919)

TIGIT and PD-1 impair tumor antigen-specific CD8^sup +^ T cells in melanoma patients

TIGIT and PD-1 impair tumor antigen-specific CD8 super( +) T cells in melanoma patients

TIGIT and PD-1 impair tumor antigen-specific [CD8.sup.+] T cells in melanoma patients

Tolerance analysis using a Computer Aided Tolerancing Software: ANATOLE 3D

Phase IB study of pembrolizumab (Pembro) and pegylated-interferon alfa-2b (Peg-IFN) in advanced melanoma (MEL)

The upregulation of the inhibitory receptors BTLA and PD-1 defines a novel subset of dysfunctional tumor antigen-specific CD8+ T cells (127.19)

Abstract 4576: Immunization with CPG in combination with MHC class I and class II peptides stimulates rapid and strong tumor antigen-specific CTL responses in melanoma patients

Suchergebnisse filtern